Published in Patient Care Law Weekly, May 2nd, 2004
Boston announced that it has enrolled 1172 patients, surpassing the required sample size of 1108. The U.S. Food and Drug Administration (FDA) has confirmed that the company has reached sufficient enrollment to meet all the required trial analyses, and that it may therefore close enrollment in the trial.
The Taxus V clinical trial expands on the Taxus IV trial, which established the safety and efficacy of the Taxus Express(2) paclitaxel-eluting stent system. Taxus V is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Patient Care Law Weekly